GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immune Design Corp (NAS:IMDZ) » Definitions » Degree of Financial Leverage

Immune Design (Immune Design) Degree of Financial Leverage : 0.00 (As of Dec. 2018)


View and export this data going back to 2014. Start your Free Trial

What is Immune Design Degree of Financial Leverage?

Degree of Financial Leverage (DFL) measures the percentage change in EPS for a unit change in Earnings Before Interest and Taxes (EBIT). Immune Design's Degree of Financial Leverage for the quarter that ended in Dec. 2018 was 0.00. The higher Degree of Financial Leverage, the more volatile earnings will be.

The industry rank for Immune Design's Degree of Financial Leverage or its related term are showing as below:

IMDZ's Degree of Financial Leverage is not ranked *
in the Biotechnology industry.
Industry Median: 0.97
* Ranked among companies with meaningful Degree of Financial Leverage only.

Immune Design Degree of Financial Leverage Historical Data

The historical data trend for Immune Design's Degree of Financial Leverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immune Design Degree of Financial Leverage Chart

Immune Design Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18
Degree of Financial Leverage
Get a 7-Day Free Trial - - - - -

Immune Design Quarterly Data
Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18
Degree of Financial Leverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Immune Design's Degree of Financial Leverage

For the Biotechnology subindustry, Immune Design's Degree of Financial Leverage, along with its competitors' market caps and Degree of Financial Leverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Immune Design's Degree of Financial Leverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Immune Design's Degree of Financial Leverage distribution charts can be found below:

* The bar in red indicates where Immune Design's Degree of Financial Leverage falls into.



Immune Design Degree of Financial Leverage Calculation

Immune Design's Degree of Financial Leverage for the quarter that ended in Dec. 2018 is calculated as:

Degree of Financial Leverage=% Change in Earnings per Share (Diluted)**/% Change in EBIT
=( -1.14 (Dec. 2018) / -1.75 (Dec. 2017) - 1 )/( -57.05 (Dec. 2018) / -52.812 (Dec. 2017) - 1 )
=-0.3486/0.0802
=-4.34***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** TTM data of EPS and EBIT was used to calculate Degree of Financial Leverage.
*** Please be aware that the Degree of Financial Leverage calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.


Immune Design  (NAS:IMDZ) Degree of Financial Leverage Explanation

Degree of Financial Leverage (DFL) is a leverage ratio that measures the sensitivity of a company’s Earnings per Share (EPS) to fluctuations in its operating income, also referred to as Earnings Before Interest and Taxes (EBIT), resulting from adjustments in its capital structure. DFL is an essential tool for companies to assess the appropriate level of debt or financial leverage in their capital structure. When EBIT remains relatively stable, it results in stable earnings and earnings per share. In such cases, the company may consider taking on substantial debt. However, for companies operating in industries with significant fluctuations in EBIT, it is advisable to keep debt at a manageable level.

The higher Degree of Financial Leverage, the more volatile earnings will be. Because interest is a fixed expense, leverage can amplify earnings and EPS. This is beneficial when EBIT is growing, but it can become problematic in tough economic conditions when EBIT is under pressure.

Be Aware

The use of financial leverage varies across different industries and business sectors, and the application of Degree of Financial Leverage (DFL) should be adjusted accordingly.


Immune Design Degree of Financial Leverage Related Terms

Thank you for viewing the detailed overview of Immune Design's Degree of Financial Leverage provided by GuruFocus.com. Please click on the following links to see related term pages.


Immune Design (Immune Design) Business Description

Traded in Other Exchanges
N/A
Address
1616 Eastlake Avenue East, Suite 310, Seattle, WA, USA, 98102
Immune Design is a clinical-stage immunotherapy company. Its focus is next-generation in vivo methods intended to enable the body's immune system to fight diseases. The company's therapies have a broad potential approach across multiple therapeutic areas. Nevertheless, the company's target is oncology, and it is developing tumor-specific cytotoxic T cells to fight cancer. The main discoveries are CMB305 and G100, immuno-oncology approaches that are believed to address the shortcomings of existing oncological therapies.
Executives
William R Ringo director
David Baltimore director AMGEN INC., ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320-1799
Edward Penhoet director ONE EMBARCADERO CENTER SUITE 3700, SAN FRANCISCO CA 94111
Susan L. Kelley director C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM MA 02451
Carlos V Paya director, officer: President and CEO C/O IMMUNE DESIGN CORP., 1616 EASTLAKE AVE. E, SUITE 310, SEATTLE WA 98102
David V Goeddel 10 percent owner, other: Managing Partner C/O COLUMN GROUP LP, 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Column Group Ii, Lp 10 percent owner 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Peter Svennilson 10 percent owner, other: Managing Partner 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Tim Kutzkey 10 percent owner, other: Managing Partner 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Column Group Ii Gp, Lp 10 percent owner, other: General Partner 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Ponoi Capital, Lp 10 percent owner 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Ponoi Management, Llc 10 percent owner, other: General Partner 1 LETTERMAN DRIVE, BUILDING D, SUITE M-900, SAN FRANCISCO CA 94129
Column Group L P 10 percent owner 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Column Group Gp, Lp 10 percent owner, other: General Partner 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Franklin M Berger director 1000 MARINA BLVD, STE 200, BRISBANE CA 94005

Immune Design (Immune Design) Headlines

From GuruFocus

RS Investment Exits LogMeIn, HMS Holdings in 3rd Quarter

By Tiziano Frateschi Tiziano Frateschi 10-04-2016